Teva Pharmaceuticals Presents Data Showing UZEDY Improves Treatment Continuity, Reduces Hospitalizations And Cuts Healthcare Costs In Schizophrenia And Bipolar I Disorder
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)The new real-world data also show that
Teva's new medicine UZEDY helps people stay on treatment longer. This could mean fewer hospital visits and lower costs for patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.